2. Academic Validation
  3. Synthesis and Evaluation of 2,6-Modified Purine 2'-C-Methyl Ribonucleosides as Inhibitors of HCV Replication

Synthesis and Evaluation of 2,6-Modified Purine 2'-C-Methyl Ribonucleosides as Inhibitors of HCV Replication

  • ACS Med Chem Lett. 2015 Nov 23;7(1):17-22. doi: 10.1021/acsmedchemlett.5b00402.
Longhu Zhou 1,  Hongwang Zhang 1,  Sijia Tao 1,  Maryam Ehteshami 1,  Jong Hyun Cho 1,  Tamara R McBrayer 2,  Philip Tharnish 2,  Tony Whitaker 2,  Franck Amblard 1,  Steven J Coats 2,  Raymond F Schinazi 1
Affiliations

Affiliations

  • 1 Center for AIDS Research, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, and Veterans Affairs Medical Center , Atlanta, Georgia 30322, United States.
  • 2 CoCrystal Pharma, Inc. , Tucker, Georgia 30084, United States.
PMID: 26819659 DOI: 10.1021/acsmedchemlett.5b00402
Abstract

A variety of 2,6-modified purine 2'-C-methylribonucleosides and their phosphoramidate prodrugs were synthesized and evaluated for inhibition of HCV RNA replication in Huh-7 cells and for cytotoxicity in various cell lines. Cellular pharmacology and HCV polymerase incorporation studies on the most potent and selective compound are reported.

Keywords

HCV; antiviral; nucleoside; phosphoramidate prodrug; purine.

Figures